IL158866A0 - Use of il-18 inhibitors for the treatment or prevention of sepsis - Google Patents

Use of il-18 inhibitors for the treatment or prevention of sepsis

Info

Publication number
IL158866A0
IL158866A0 IL15886602A IL15886602A IL158866A0 IL 158866 A0 IL158866 A0 IL 158866A0 IL 15886602 A IL15886602 A IL 15886602A IL 15886602 A IL15886602 A IL 15886602A IL 158866 A0 IL158866 A0 IL 158866A0
Authority
IL
Israel
Prior art keywords
sepsis
prevention
treatment
inhibitors
syndrone
Prior art date
Application number
IL15886602A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of IL158866A0 publication Critical patent/IL158866A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15886602A 2001-05-16 2002-05-16 Use of il-18 inhibitors for the treatment or prevention of sepsis IL158866A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29146301P 2001-05-16 2001-05-16
PCT/US2002/015556 WO2002092008A2 (en) 2001-05-16 2002-05-16 Use of il-18 inhibitors for the treatement or prevention of sepsis

Publications (1)

Publication Number Publication Date
IL158866A0 true IL158866A0 (en) 2004-05-12

Family

ID=23120395

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15886602A IL158866A0 (en) 2001-05-16 2002-05-16 Use of il-18 inhibitors for the treatment or prevention of sepsis
IL158866A IL158866A (en) 2001-05-16 2003-11-13 Use of 18IL inhibitors for the preparation of drugs for the treatment or prevention of sepsis

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL158866A IL158866A (en) 2001-05-16 2003-11-13 Use of 18IL inhibitors for the preparation of drugs for the treatment or prevention of sepsis

Country Status (20)

Country Link
US (1) US20030008822A1 (uk)
EP (1) EP1425028B1 (uk)
JP (1) JP4502580B2 (uk)
KR (1) KR100877033B1 (uk)
CN (1) CN100556450C (uk)
AT (1) ATE451930T1 (uk)
BR (1) BR0210904A (uk)
CA (1) CA2446942C (uk)
CY (1) CY1109713T1 (uk)
DE (1) DE60234778D1 (uk)
DK (1) DK1425028T3 (uk)
EA (1) EA009125B1 (uk)
ES (1) ES2334773T3 (uk)
HK (1) HK1066723A1 (uk)
IL (2) IL158866A0 (uk)
MX (1) MXPA03010575A (uk)
PT (1) PT1425028E (uk)
SI (1) SI1425028T1 (uk)
UA (1) UA85531C2 (uk)
WO (1) WO2002092008A2 (uk)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1331943A4 (en) 2000-10-11 2005-01-26 Viron Therapeutics Inc NUCLEIC ACID MOLECULES AND POLYPEPTIDES FOR IMMUNOMODULATION
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
CA2524403C (en) 2003-05-13 2013-07-09 Applied Research Systems Ars Holding N.V. Active variants of the il-18 binding protein and medical uses thereof
EP2266606B1 (en) 2003-05-15 2014-09-10 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
US7482376B2 (en) * 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
WO2005110450A1 (ja) * 2004-05-17 2005-11-24 Keio University 医薬組成物及び治療方法
FI116804B (fi) * 2004-05-18 2006-02-28 Ekspansio Engineering Ltd Oy Materiaalikappaleiden eri suuntiin osoittavien pintojen optinen tarkastus
US7691611B2 (en) 2005-06-03 2010-04-06 Ares Trading S.A. Production of recombinant IL-18 binding protein
JP5091127B2 (ja) 2005-06-10 2012-12-05 アレス トレーディング ソシエテ アノニム Ｉｌ−１８結合タンパク質の精製のための方法
WO2008119851A1 (es) 2007-03-28 2008-10-09 Universidad De Barcelona Producto proteico para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados
CL2008002153A1 (es) 2007-07-24 2009-06-05 Amgen Inc Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
EP2608807A1 (en) 2010-08-27 2013-07-03 Stem Centrx, Inc. Notum protein modulators and methods of use
KR101451357B1 (ko) * 2011-02-18 2014-10-15 주식회사 스템디알 Ｓｉｒｔ１ 발현 유도 물질을 포함하는 패혈증 또는 패혈증 쇼크의 예방 또는 치료용 조성물
WO2013169077A1 (ko) 2012-05-11 2013-11-14 주식회사 카엘젬백스 악액질 예방 또는 치료용 조성물
KR102578891B1 (ko) 2012-05-11 2023-09-15 주식회사 젬백스앤카엘 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
US10967000B2 (en) 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
EP2987497B1 (en) 2013-04-19 2018-12-26 Gemvax & Kael Co., Ltd. Composition for treating and preventing ischemic damage
WO2014196841A1 (en) 2013-06-07 2014-12-11 Kael-Gemvax Co., Ltd. Biological markers useful in cancer immunotherapy
JP6495899B2 (ja) 2013-06-21 2019-04-03 ジェムバックス アンド カエル カンパニー，リミティド ホルモン分泌調節剤、及びそれを含む組成物
EP3978526A1 (en) * 2013-09-05 2022-04-06 AB2 Bio SA Il-18 binding protein (il-18bp) in inflammatory diseases
EP3061459B1 (en) 2013-10-23 2019-12-11 Gemvax & Kael Co., Ltd. Composition for treating and preventing benign prostatic hyperplasia
KR102694658B1 (ko) 2013-11-22 2024-08-14 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
EP3085380B1 (en) 2013-12-17 2020-06-17 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
GB201400997D0 (en) * 2014-01-21 2014-03-05 Vib Vzw Targeting of interleukin-1 and -18 in treatment of septic shock
JP6420459B2 (ja) 2014-04-11 2018-11-07 ジェムバックス アンド カエル カンパニー，リミティド 線維症抑制活性を有するペプチド及びこれを含む組成物
US10662223B2 (en) 2014-04-30 2020-05-26 Gemvax & Kael Co., Ltd. Composition for organ, tissue, or cell transplantation, kit, and transplantation method
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
EP3263122B1 (en) 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptide for preventing hearing loss, and composition comprising same
US10882905B2 (en) 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
US11015179B2 (en) 2015-07-02 2021-05-25 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
JP7114481B2 (ja) 2016-04-07 2022-08-08 ジェムバックス アンド カエル カンパニー，リミティド テロメラーゼ活性の増加及びテロメアの延長の効能を有するペプチド、及びこれを含む組成物
EP3541407A1 (en) 2016-11-18 2019-09-25 Universitat de Barcelona Combined cd6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes
CN107715105B (zh) * 2017-10-26 2020-11-24 重庆医科大学 Il-34在制备治疗或预防脓毒症药物中的应用
CN109954131B (zh) * 2017-12-14 2023-05-02 深圳市中科艾深医药有限公司 一种肿瘤坏死因子相关凋亡诱导配体拮抗剂作为脓毒血症治疗药物的应用
CN111012899A (zh) * 2020-01-08 2020-04-17 重庆医科大学 Il-38的新用途
WO2024148232A2 (en) 2023-01-06 2024-07-11 Alector Llc Anti-il18 binding protein antibodies and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
JPH05503512A (ja) * 1989-11-29 1993-06-10 ブリガム・アンド・ウイメンズ・ホスピタル 白血球接着阻害因子としての［ａｌａ　ｉｌ―８］↓７↓７
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
ATE317381T1 (de) * 1996-10-11 2006-02-15 Warner Lambert Co Sulfonamid-substituierte asparaginsäuren als inhibitoren von interleukin-1beta-konvertierenden enzymen
SK122199A3 (en) * 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
US6054487A (en) 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
KR101111103B1 (ko) * 2000-02-10 2012-02-13 아보트 러보러터리즈 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법
TR200502508T2 (tr) * 2000-02-21 2007-04-24 Applied Research Systems Ar� Holding N.V. IL-18 İnhibitörlerinin kullanımı.
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
CY1109713T1 (el) 2014-08-13
EA009125B1 (ru) 2007-10-26
WO2002092008A2 (en) 2002-11-21
US20030008822A1 (en) 2003-01-09
UA85531C2 (uk) 2009-02-10
WO2002092008A3 (en) 2004-04-08
EP1425028B1 (en) 2009-12-16
DK1425028T3 (da) 2010-03-01
EP1425028A2 (en) 2004-06-09
CN100556450C (zh) 2009-11-04
KR100877033B1 (ko) 2009-01-07
ES2334773T3 (es) 2010-03-16
MXPA03010575A (es) 2005-03-07
ATE451930T1 (de) 2010-01-15
EP1425028A4 (en) 2006-03-01
HK1066723A1 (en) 2005-04-01
DE60234778D1 (de) 2010-01-28
BR0210904A (pt) 2005-08-16
KR20040045400A (ko) 2004-06-01
EA200301248A1 (ru) 2005-06-30
CN1529611A (zh) 2004-09-15
IL158866A (en) 2011-01-31
SI1425028T1 (sl) 2010-02-26
CA2446942C (en) 2010-07-20
PT1425028E (pt) 2010-01-06
JP4502580B2 (ja) 2010-07-14
CA2446942A1 (en) 2002-11-21
JP2004531546A (ja) 2004-10-14

Similar Documents

Publication Publication Date Title
IL158866A0 (en) Use of il-18 inhibitors for the treatment or prevention of sepsis
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
MXPA04004370A (es) Derivados policiclicos de guanina inhibidores de fosfodiesterasa v.
CA2457944A1 (en) Polycyclic guanine phosphodiesterase v inhibitors
NO20005255L (no) Pyrazolpyrimidin-CGMPPDE5-inhibitorer for behandling av seksuell dysfunksjon
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
WO2003105840A3 (en) SPHINGOSINE KINASE INHIBITORS
MXPA04002137A (es) Inhibidores de glicogen sintasa quinasa-3 (gsk-3) para el tratamiento del glaucoma.
UA66846C2 (uk) Похідні імідазопіридину, які інгібують секрецію шлункової кислоти
WO2002030353A3 (en) NF-λB INHIBITORS
MXPA03002814A (es) Derivados de morfolin-acetamida para el tratamiento de enfermedades inflamatorias.
IL157320A0 (en) Rapid-onset medicament for the treatment of sexual dysfunction
WO2003065987A3 (en) Granzyme b inhibitors
MXPA03006817A (es) Metodo de tratamiento de enfermedades inflamatorias e inmunes usando inhibidores de la ikb cinasa (ikk).
MXPA04002562A (es) Combinacion de un pde-4 y nsaid.
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
WO2000011000A3 (en) New compounds
WO2000010999A3 (en) New compounds
WO2002068476A3 (en) Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
SE0102808D0 (sv) New compounds
YU57803A (sh) Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja
EP1476149A4 (en) SUBSTITUTED HYDRAZONES AS INHIBITORS OF CYCLOOXYGENASE-2
WO2001044235A3 (en) Agents and methods for the treatment of proliferative diseases

Legal Events

Date Code Title Description
FF Patent granted